Microalbuminuria: A parameter that has changed diabetes care

Diabetes Research and Clinical Practice

Volumn 107, Issue 1, 2015, Pages 1-8

  Parving, Hans Henrik ^a,c   Persson, Frederik ^b   Rossing, Peter ^b,c,d  

^a Rigshospitalet   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Diabetic nephropathy

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTILIPEMIC AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE ACTIVITY; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEOMICS; REMISSION; RENAL PROTECTION; RENAL SYSTEM PARAMETERS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; URINARY ALBUMIN EXCRETION; ALBUMINURIA; BLOOD; CARDIOVASCULAR DISEASE; GLUCOSE BLOOD LEVEL; METABOLISM; RISK FACTOR; URINE;

ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; HUMANS; RISK FACTORS;

EID: 84922764517     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.10.014     Document Type: Review

References (58)

1. Keen H., Chlouverakis C., Fuller J.H., Jarrett R.J. The concomitants of raised blood sugar: studies in newly-detected hyperglycaemics. II. Urinary albumin excretion, blood pressure and their relation to blood sugar levels. Guy's Hosp Rep 1969, 118:247-254.
2. Kussman M.J., Goldstein H.H., Gleason R.E. The clinical course of diabetic nephropathy. JAMA 1976, 236:1861-1863.
3. Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982, 285:685-688.
4. Parving H.-H., Andersen A.R., Smidt U.M., Svendsen PAa. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983, 1175-1179.
5. Viberti G.C., Hill R.D., Jarrett R.J., Argyropoulos A., Mahmud U., Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982, 1430-1432.
6. Parving H.-H., Oxenbøll B., Svendsen PAa, Christiansen J.S., Andersen A.R. Early detection of patients at risk of developing diabetic nephropathy. Acta Endocrinol 1982, 100:550-555.
7. Mogensen C.E., Christensen C.K. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984, 311:89-93.
8. Parving H.-H., Mauer M., Fioretto P., Rossing P., Ritz E. Diabetic nephropathy. Brenner and rector: the kidney 2012, 1411-1454. Elsevier, Philadelphia, PA. M.W. Taal (Ed.).
9. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter, Suppl 2013; 3(1):5-14.
10. Lambers Heerspink H.J., Gansevoort R.T., Brenner B.M., Cooper M.E., Parving H.-H., Shahinfar S., et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 2010, 21(8):1355-1360.
11. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012; 60(5):850-86.
12. MacIsaac R.J., Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 2011, 20(3):246-257.
13. MacIsaac R.J., Ekinci E.I., Jerums G. Progressive diabetic nephropathy How useful is microalbuminuria?.: contra. Kidney Int 2014, 86(1):50-57.
14. Carville S., Wonderling D., Stevens P. Early identification and management of chronic kidney disease in adults: summary of updated NICE guidance. Br Med J 2014, 349:g4507.
15. Molitch M.E., Steffes M., Sun W., Rutledge B., Cleary P., de Boer I.H., et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010, 33(7):1536-1543.
16. Nieuwdorp M., Mooij H.L., Kroon J., Atasever B., Spaan J.A., Ince C., et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006, 55(4):1127-1132.
17. Thomsen O.F., Andersen A.R., Christiansen J.S., Deckert T. Renal changes in long-term type 1 (insulin-dependent) diabetic patients with and without clinical nephropathy: a light microscopic, morphometric study of autopsy material. Diabetologia 1984, 26(5):361-365.
18. Bohle A., Wehrmann M., Bogenschutz O., Batz C., Muller C.A., Muller G.A. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991, 187(2-3):251-259.
19. Taft J.L., Nolan C.J., Yeung S.P., Hewitson T.D., Martin F.I.R. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994, 43:1046-1051.
20. Roscioni S.S., Lambers Heerspink H.J., de Zeeuw D. Microalbuminuria: target for renoprotective therapy PRO. Kidney Int 2014, 86(1):40-49.
21. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989, 32:219-226.
22. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski lecture 2005. Diabetologia 2006, 49(1):11-19.
23. Dinneen S.F., Gerstein H.C. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997, 157:1413-1418.
24. Parving H.-H. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998, 41:745-759.
25. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.-H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
26. Astrup A.S., Tarnow L., Rossing P., Hansen B.V., Hilsted J., Parving H.-H. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006, 29(2):334-339.
27. Giunti S., Bruno G., Veglio M., Gruden G., Webb D.J., Livingstone S., et al. Electrocardiographic left ventricular hypertrophy in type 1 diabetes: prevalence and relation to coronary heart disease and cardiovascular risk factors: the Eurodiab IDDM Complications Study. Diabetes Care 2005, 28(9):2255-2257.
28. Wang P.H., Lau J., Chalmers T.C. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993, 341:1306-1309.
29. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-86.
30. The Diabetes Control and Complications Trial Research Group/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342:381-9.
31. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000, 321(7258):405-412.
32. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
33. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. The ADVANCE Collaborative Group.
34. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-59.
35. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139.
36. Perkovic V., Heerspink H.L., Chalmers J., Woodward M., Jun M., Li Q., et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013, 83(3):517-523.
37. Coca S.G., Ismail-Beigi F., Haq N., Krumholz H.M., Parikh C.R. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012, 172(10):761-769.
38. Chaturvedi N., Sjolie A.-K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998, 351:28-31.
39. Chaturvedi N., Porta M., Klein R., Orchard T., Fuller J., Parving H.-H., et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008, 372(9647):1394-1402.
40. Mauer M., Zinman B., Gardiner R., Suissa S., Sinaiko A., Strand T., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361(1):40-51.
41. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-9.
42. Ruggenenti P., Fassi A., Ilieva A.P., Bruno S., Iliev I.P., Brusegan V., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351(19):1941-1951.
43. Patel A., MacMahon C.G., Chalmers S., Neal J., Woodward B.M., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370(9590):829-840.
44. Bilous R., Chaturvedi N., Sjolie A.K., Fuller J., Klein R., Orchard T., et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009, 151(1):11-14.
45. Haller H., Ito S., Izzo J.L., Januszewicz A., Katayama S., Menne J., et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011, 364(10):907-917.
46. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134(5):370-9.
47. Mathiesen E.R., Hommel E., Hansen H.P., Smidt U.M., Parving H.-H. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999, 319:24-25.
48. Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993, 118:577-581.
49. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. Br Med J 1998; 317(7160):713-20.
50. Parving H.-H., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 Diabetes. N Engl J Med 2001, 345:870-878.
51. Rossing K., Christensen P.K., Andersen S., Hovind P., Hansen H.P., Parving H.-H. Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in patients with type 2 diabetes and microalbuminuria study. Diabetes Care 2003, 26(3):569-574.
52. Andersen S., Brochner-Mortensen J., Parving H.-H. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003, 26(12):3296-3302.
53. Hellemons M.E., Persson F., Bakker S.J., Rossing P., Parving H.-H., de Z.D., et al. Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. Diabetes Care 2011, 34(9):2078-2083.
54. Gaede P., Tarnow L., Vedel P., Parving H.-H., Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004, 19(11):2784-2788.
55. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care 2014; 37(Suppl 1):S14-S80.
56. Gaede P., Vedel P., Parving H.-H., Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999, 353(9153):617-622.
57. Gaede P., Lund-Andersen H., Parving H.-H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
58. Schmieder R., Schutte R., Schumacher H., Böhm M., Mancia G., Weber M., et al. Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. Diabetologia 2014, 57(10):2019-2029.